F2G's Unattributed VC - II Round

F2G raised a round of funding on September 05, 2012.

F2G is advancing F901318, a novel clinical stage candidate for the treatment of invasive aspergillosis – a serious pulmonary infection caused by Aspergillus, a common fungus that affects people with…

Articles about F2G's Unattributed VC - II Round: